Anti-Fibrinolytic Drugs - Tanzania

The Anti-Fibrinolytic Drugs market in Tanzania is expected to witness a significant increase in revenue, reaching a projected amount of US$3.34m by the year 2024.
Furthermore, it is anticipated that the market will continue to grow steadily with an annual growth rate of 5.61% (CAGR 2024-2029), resulting in a market volume of US$4.39m by 2029.
When compared to other countries globally, it is noteworthy that United States is projected to generate the highest revenue in the Anti-Fibrinolytic Drugs market, amounting to US$9.86bn in the year 2024.
Tanzania's demand for anti-fibrinolytic drugs is rising due to an increasing prevalence of bleeding disorders in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs are a vital part of the global pharmaceutical industry. In Tanzania, the market for these drugs has been steadily growing.

Customer preferences: The demand for Anti-Fibrinolytic Drugs in Tanzania is driven by the increasing prevalence of bleeding disorders such as hemophilia and trauma-related bleeding. The drugs are also used during surgeries to prevent excessive bleeding. Patients with these conditions require regular medication, which has led to a steady increase in demand for Anti-Fibrinolytic Drugs.

Trends in the market: The Anti-Fibrinolytic Drugs market in Tanzania is experiencing a shift from brand-name drugs to generic drugs. This shift is driven by the high cost of brand-name drugs and the availability of cheaper generic alternatives. The Tanzanian government has also been promoting the use of generic drugs to reduce healthcare costs. This trend is expected to continue as more generic drugs become available in the market.

Local special circumstances: Tanzania has a high burden of diseases such as malaria, HIV/AIDS, and tuberculosis, which has resulted in a significant strain on the healthcare system. The government has been investing in the healthcare sector to improve access to healthcare services, including medication. The country's healthcare infrastructure is still developing, and there is a need to increase the availability of healthcare services in rural areas.

Underlying macroeconomic factors: Tanzania's economy has been growing steadily over the past few years, with a focus on developing industries such as agriculture, mining, and tourism. The growth of these industries has led to an increase in disposable income, which has resulted in an increase in demand for healthcare services, including medication. The government has also been investing in the healthcare sector to improve access to healthcare services, which has led to an increase in demand for Anti-Fibrinolytic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.